Stearic Acid
Introduction
Section titled “Introduction”Stearic acid (C18:0) is a common saturated fatty acid, a fundamental organic compound found extensively in various animal and plant fats. It plays a significant role in biological systems.
Biological Basis
Section titled “Biological Basis”Within the human body, stearic acid is a key component in membrane lipid biosynthesis, contributing to the structural integrity of cell membranes.[1]It also serves as an important energy substrate and can be metabolically converted into other fatty acids, such as oleic acid (C18:1), through desaturation processes. Genetic variations, particularly within theFADS (Fatty Acid Desaturase) gene cluster, are known to influence the metabolism and composition of various fatty acids, including polyunsaturated fatty acids, in phospholipids. [2] For example, the FADS1 gene, part of this cluster, codes for the fatty acid delta-5 desaturase, an enzyme crucial for the metabolism of long-chain omega-3 and omega-6 fatty acids [3]A specific single nucleotide polymorphism,rs174548 , located within a linkage disequilibrium block containing the FADS1gene, has been strongly associated with glycerophospholipid concentrations. The minor allele variant ofrs174548 is linked to a reduced efficiency of the fatty acid delta-5 desaturase reaction, which subsequently impacts the concentrations of various phospholipids and their polyunsaturated fatty acid side chains[3]
Clinical Relevance
Section titled “Clinical Relevance”Variations in the genes governing fatty acid metabolism, such as those within the FADS1-FADS2 gene cluster, are clinically relevant due to their established associations with lipid concentrations and the risk of dyslipidemia [4]These genetic factors can significantly affect an individual’s overall lipid profile, which is a critical biomarker for assessing the risk of cardiovascular disease. Understanding these genetic influences is essential for unraveling the complex interplay between dietary intake, an individual’s genetic makeup, and their metabolic health.
Social Importance
Section titled “Social Importance”The investigation into stearic acid and its genetic determinants holds substantial social importance. It contributes valuable insights into how dietary fat consumption interacts with an individual’s unique genetic profile to shape health outcomes. This knowledge is instrumental in developing personalized nutrition guidelines and public health recommendations aimed at preventing and managing metabolic and cardiovascular diseases. By identifying specific genetic variants that influence fatty acid metabolism, research can pave the way for more targeted interventions and a deeper understanding of complex polygenic traits.
Limitations
Section titled “Limitations”Methodological and Statistical Considerations
Section titled “Methodological and Statistical Considerations”Genome-wide association studies (GWAS), while powerful for identifying genetic variants, are subject to several methodological and statistical constraints that can impact the interpretation and generalizability of their findings. Many studies are conducted in “moderate-sized” cohorts, and the use of 100K SNP arrays may be insufficient to exclude real genetic associations, potentially leading to missed genes due to limited genomic coverage. [5] The extensive number of statistical tests performed in GWAS also introduces a multiple testing problem, which can be compounded by conducting only sex-pooled rather than sex-specific analyses, thereby risking the non-detection of genuine associations that may be specific to one sex. [6]
The ultimate validation of GWAS findings necessitates replication in independent cohorts, a principle considered the “gold standard” [7] as initial exploratory analyses require re-examination in other populations to confirm their veracity. [7] Furthermore, inconsistencies in analytical standardization, such as variations in age adjustments, methods for handling outliers, or availability of information on lipid-lowering therapies, can introduce heterogeneity across studies. [4] Genotype imputation, while necessary to compare different marker sets, introduces an inherent error rate, potentially affecting the precision of allele assignments and downstream association analyses. [8]
Generalizability and Phenotype Specificity
Section titled “Generalizability and Phenotype Specificity”A significant limitation across many genetic studies is the predominant focus on populations of “self-reported European ancestry”. [4] While some research has attempted to extend findings to multiethnic samples, the generalizability of these associations to diverse ancestral groups remains limited, as genetic architecture and allele frequencies can differ substantially across populations. [4] This inherent ancestry bias restricts the broader applicability of discovered variants, underscoring the critical need for more diverse cohorts to fully unravel global genetic influences on metabolic traits.
The precision and scope of phenotype measurement also present challenges. While exclusion of individuals on lipid-lowering therapies is a standard practice, this information was not consistently available or uniformly applied across all cohorts, potentially confounding associations with natural lipid levels. [8] Some studies utilized targeted metabolomics platforms for specific metabolites or approximated enzymatic activity using metabolite ratios, which, while valuable, are indirect measures and may not fully capture the complexity of underlying biochemical pathways. [3] Additionally, statistical transformations were frequently required to normalize non-normally distributed protein levels, which can affect the direct interpretation of findings derived from raw phenotypic data. [9]
Unexplained Heritability and Remaining Knowledge Gaps
Section titled “Unexplained Heritability and Remaining Knowledge Gaps”Despite the identification of numerous genetic loci, the variants discovered through GWAS typically account for only a small proportion, often “about 5–8%,” of the total variation in complex traits like lipid levels. [8]This substantial “missing heritability” indicates that a significant portion of genetic influence on stearic acid levels, and related metabolic traits, remains unexplained. The potential contributors to this gap include a much larger number of common variants each exerting individually “small effect” sizes, rarer variants with larger effects that are not adequately captured by current common SNP arrays, or complex interactions between genetic factors and environmental exposures.[8]
Furthermore, the precise functional variants and mechanisms underlying the identified associations often remain elusive, particularly in genomic regions containing multiple candidate genes. [8] To address these knowledge gaps, future research must involve comprehensive resequencing of exons and conserved regions in large populations to systematically identify all potential functional variants within each associated locus. [8] Such detailed genetic characterization, combined with rigorous functional studies, is essential for pinpointing causal genes and elucidating their biological roles, thereby advancing our understanding of the complete genetic architecture of complex metabolic traits. [7]
Variants
Section titled “Variants”Genetic variations can significantly influence an individual’s metabolic profile, impacting the way the body processes fats, sugars, and other essential molecules. Among these, single nucleotide polymorphisms (SNPs) in genes likePKD2L1 and PPP1R3B-DT have garnered attention for their potential roles in diverse physiological processes and their indirect connections to lipid metabolism. Genome-wide association studies frequently investigate how genetic variants relate to the intricate profiles of metabolites, including various phospholipids and fatty acids, in human serum. [3] Such research aims to uncover the genetic underpinnings of metabolic variations that could impact individual fatty acid composition. [3]
The PKD2L1gene, or Polycystic Kidney Disease 2 Like 1, encodes a non-selective, calcium-permeable ion channel, which is a member of the transient receptor potential (TRP) channel family. These channels play crucial roles in various sensory functions, including taste perception (e.g., sour taste), and are involved in cellular signaling pathways across many tissues. The variantrs603424 located within or near PKD2L1 may influence the expression or function of this channel, thereby subtly altering cellular calcium signaling. Since calcium signaling pathways are critical regulators of numerous metabolic processes, including the synthesis, breakdown, and transport of lipids, changes in PKD2L1 activity due to rs603424 could indirectly impact the body’s overall energy balance and lipid homeostasis. This could potentially affect the availability or metabolism of specific fatty acids, such as stearic acid, which is a common saturated fatty acid integral to cellular membranes and energy storage.
Another variant, rs2169387 , is associated with the PPP1R3B-DT locus, which refers to a divergent transcript in the region of the PPP1R3B gene (Protein Phosphatase 1 Regulatory Subunit 3B). While PPP1R3B-DT itself may be a long non-coding RNA, the core PPP1R3B gene is a key regulator of glycogen metabolism, primarily in the liver. It functions by modulating the activity of protein phosphatase 1 (PP1), which in turn dephosphorylates and activates glycogen synthase, a critical enzyme for glycogen synthesis. Therefore, rs2169387 might affect the expression or function of PPP1R3B-DT, thereby indirectly modulating the activity of PPP1R3Band subsequently influencing glucose homeostasis. The intricate relationship between glucose and lipid metabolism means that altered glucose handling can shift metabolic pathways towards increased fatty acid synthesis or storage. Consequently, a variant likers2169387 could affect the body’s overall lipid profile and the abundance of specific fatty acids like stearic acid by impacting the availability of metabolic precursors or regulatory signals.[3] Comprehensive metabolomic studies frequently analyze a broad spectrum of lipids, including various fatty acyl-chains and phospholipids, to identify genetic determinants of metabolic phenotypes. [3]
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs603424 | PKD2L1 | fatty acid amount metabolite measurement phospholipid amount heel bone mineral density coronary artery disease |
| rs2169387 | PPP1R3B-DT | low density lipoprotein cholesterol measurement depressive symptom measurement, low density lipoprotein cholesterol measurement social deprivation, triglyceride measurement total cholesterol measurement high density lipoprotein cholesterol measurement |
Classification, Definition, and Terminology
Section titled “Classification, Definition, and Terminology”Definition and Structural Nomenclature of Fatty Acids
Section titled “Definition and Structural Nomenclature of Fatty Acids”The fundamental components of lipid side chains, such as various fatty acids, are precisely defined through a standardized nomenclature system. [3] This system abbreviates lipid side chain composition as Cx:y, where ‘x’ represents the total number of carbon atoms present in the side chain, and ‘y’ denotes the count of double bonds. [3] This operational definition allows for the consistent characterization of individual fatty acids and their integration into more complex lipid structures, forming part of the broader spectrum of endogenous metabolites routinely quantified in human serum. [3]
Within this conceptual framework, fatty acid residues are integral to various glycerol moieties, contributing to molecules classified as diacyl (aa), acyl-alkyl (ae), or dialkyl (ee) lipids, depending on the ester and ether bonds present. [3] The presence of a single fatty acid residue, referred to as acyl (a) or alkyl (e), also follows specific abbreviation conventions. [3] Understanding this precise structural terminology is essential for distinguishing between different lipid species and their roles in biological systems.
Classification and Functional Categorization of Lipids
Section titled “Classification and Functional Categorization of Lipids”Fatty acids are classified based on their composition and their role in forming complex lipids such as phospholipids. For instance, the FADS1 FADS2 gene cluster is notably associated with variations in the fatty acid composition within phospholipids. [2] This highlights how individual fatty acids contribute to the overall lipid profile and are subject to genetic influences. [2] Further classification differentiates phospholipids by their acyl chain characteristics, such as the number of carbons and double bonds, exemplified by various phosphatidylcholines (e.g., PC aa C34:4, PC aa C38:6) and plasmalogen/plasmenogen phosphatidylcholines (e.g., PC ae C36:4). [3]
These lipid classifications extend to their metabolic context, impacting broader lipid traits such as total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides.[10] The genetic variation in fatty acid metabolism can influence these profiles, linking specific fatty acid classifications to metabolic health outcomes. [11]Such a detailed nosological system for lipids enables researchers to categorize and study their physiological significance and disease associations.
Measurement and Analytical Terminology for Metabolites
Section titled “Measurement and Analytical Terminology for Metabolites”The quantification of fatty acids and their derivatives is achieved through sophisticated measurement approaches, primarily targeted quantitative metabolomics platforms utilizing electrospray ionization (ESI) tandem mass spectrometry (MS/MS). [3] This methodology allows for the determination of fasting serum concentrations for a wide array of endogenous metabolites, encompassing categories such as acylcarnitines, amino acids, and numerous phosphatidylcholines. [3] These measurements provide crucial biomarker data for assessing metabolic status in research settings.
Specific terminology for measurement and analysis acknowledges certain limitations; for instance, this technology cannot always ascertain the precise position of double bonds or the exact distribution of carbon atoms across different fatty acid side chains. [3] Furthermore, distinguishing between stereochemical differences or isobaric fragments can sometimes lead to ambiguous assignments in metabolite mapping. [3] Therefore, a comprehensive understanding of these analytical criteria and their inherent constraints is essential for the accurate interpretation of metabolomic profiles.
Biological Background
Section titled “Biological Background”Genetic Determinants of Lipid Profiles
Section titled “Genetic Determinants of Lipid Profiles”The concentrations of various lipids in the human body, including fatty acids like stearic acid, are significantly influenced by underlying genetic factors. Research has identified specific genetic loci that contribute to the variability in circulating lipid levels.[8] These genetic determinants play a fundamental role in shaping an individual’s lipid profile, impacting how lipids are synthesized, transported, and catabolized within the body. The identification of these loci provides insights into the complex genetic architecture that underlies overall lipid metabolism. [8]
Enzymatic Regulation in Lipid Metabolism
Section titled “Enzymatic Regulation in Lipid Metabolism”Key biomolecules, particularly enzymes, are central to the dynamic processes of lipid metabolism and the maintenance of lipid homeostasis. Lecithin:cholesterol acyltransferase (LCAT) is a critical enzyme responsible for the esterification of free cholesterol within lipoproteins.[12] This enzymatic action is essential for the proper transport of cholesterol in the blood and for the process of reverse cholesterol transport, which helps remove excess cholesterol from peripheral tissues. Therefore, LCAT activity directly impacts the composition and function of circulating lipoproteins and overall lipid profiles. [12]
Cellular and Systemic Lipid Homeostasis
Section titled “Cellular and Systemic Lipid Homeostasis”The intricate balance of lipid concentrations, encompassing components such as stearic acid, is crucial for proper cellular function and systemic health. Cellular functions related to lipid uptake, synthesis, and storage are tightly regulated to maintain this delicate homeostatic state. Disruptions in these regulatory networks, whether due to genetic predispositions or enzymatic deficiencies, can lead to imbalances in lipid profiles throughout the body.[8] These systemic consequences can affect various tissues and organs, altering their metabolic activity and overall physiological well-being.
Pathophysiological Links to Cardiovascular Disease
Section titled “Pathophysiological Links to Cardiovascular Disease”Imbalances in lipid concentrations, often influenced by genetic factors and enzyme activity, are directly implicated in the development of pathophysiological conditions, particularly coronary artery disease. Elevated or dysregulated lipid profiles can contribute to the formation of atherosclerotic plaques in arterial walls.[8] The molecular pathology observed in conditions like LCATdeficiency syndromes further illustrates how altered lipid metabolism can lead to severe systemic disease mechanisms, impacting cardiovascular health and increasing the risk of cardiac events.[12]Understanding these lipid-related disease mechanisms is vital for prevention and treatment strategies.
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Fatty Acid Metabolic Pathways
Section titled “Fatty Acid Metabolic Pathways”The metabolism of fatty acids, including saturated long-chain fatty acids like stearic acid (C18:0), involves intricate networks of synthesis, modification, and breakdown pathways crucial for energy storage, membrane structure, and signaling molecules. A central mechanism is the desaturation of fatty acids, regulated by the fatty acid desaturase (FADS) gene cluster, including FADS1 and FADS2, which are strongly associated with the composition of fatty acids in phospholipids. [2] For instance, FADS1 catalyzes the delta-5 desaturase reaction, converting eicosatrienoyl-CoA (C20:3) into arachidonyl-CoA (C20:4), a critical step in producing long-chain polyunsaturated fatty acids from essential dietary precursors. [3] These desaturation events are fundamental for generating the diverse lipid species necessary for biological function, affecting overall metabolic flux and subsequent phosphatidylcholine biosynthesis, where specific glycerophosphatidylcholines act as modified substrates and products of these desaturase reactions. [3]
Fatty acid catabolism provides energy through beta-oxidation, a process initiated by the binding of fatty acids to free carnitine for transport into mitochondria.[3] Enzymes such as medium-chain acyl-CoA dehydrogenase (MCAD) are pivotal in this pathway, processing acylcarnitines as substrates. Genetic variants affecting MCAD activity can impact the efficiency of fatty acid breakdown, leading to altered concentrations of specific acylcarnitines, which serves as a biomarker for enzyme turnover. [13] These metabolic pathways are tightly regulated to maintain cellular energy homeostasis and lipid balance, with genetic polymorphisms often revealing subtle yet significant alterations in enzymatic efficiencies and metabolic flux control.
Lipid Homeostasis and Transport Mechanisms
Section titled “Lipid Homeostasis and Transport Mechanisms”Maintaining proper lipid homeostasis involves complex regulatory and transport mechanisms, influencing circulating cholesterol and sterol levels. The ABCG5 and ABCG8genes encode ATP-binding cassette transporters that form a functional complex vital for the efflux of dietary cholesterol and noncholesterol sterols from the intestine and liver, thereby controlling systemic sterol load.[14] Dysfunctions in this transport system, such as mutations in ABCG5, are known to cause sitosterolemia, a monogenic disorder characterized by abnormal absorption and accumulation of plant sterols. [14] Beyond sterol transport, the mevalonate pathway, responsible for cholesterol biosynthesis, is critically regulated by 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) [15]with common genetic variants affecting its alternative splicing and impacting low-density lipoprotein cholesterol levels.[16]
Further contributing to lipid regulation are enzymes like lecithin:cholesterol acyltransferase (LCAT), essential for cholesterol esterification within high-density lipoproteins, where deficiencies can lead to severe lipid disorders such as fish eye disease caused by specific amino acid exchanges.[12] Moreover, apolipoprotein CIII (APOC3) is a key regulator of triglyceride metabolism, with its overexpression leading to hypertriglyceridemia by diminishing the fractional catabolic rate of very low-density lipoproteins.[17] Similarly, angiopoietin-like protein 4 (ANGPTL4) functions as a potent hyperlipidemia-inducing factor through its inhibitory effects on lipoprotein lipase.[18] These diverse mechanisms illustrate the sophisticated control over lipid levels, involving a coordinated interplay of synthesis, transport, and catabolic enzymes.
Transcriptional and Post-Translational Regulation
Section titled “Transcriptional and Post-Translational Regulation”Gene expression and protein activity are meticulously regulated to control fatty acid and lipid metabolism, often through transcriptional and post-translational modifications. Transcription factors like hepatocyte nuclear factor 4 alpha (HNF4α) and hepatocyte nuclear factor 1 alpha (HNF1α) are indispensable for maintaining hepatic gene expression, lipid homeostasis, and regulating bile acid and plasma cholesterol metabolism. [19] These nuclear receptors orchestrate a hierarchical regulatory network that fine-tunes the cellular response to metabolic cues. Beyond transcriptional control, protein modifications play a crucial role, such as the phosphorylation of Pleckstrin, which is required for its association with plasma membranes and induction of membrane projections. [20]
Post-translational modifications also govern the function and stability of metabolic enzymes and signaling proteins. For example, the ubiquitination pathway, involving proteins like parkin, is critical for protein degradation and quality control, and its dysregulation is implicated in disease processes.[21]Other regulatory interactions include the phosphorylation of Heat Shock Protein-90 by thyroid-stimulating hormone (TSH) in thyroid cells[22]and the interaction of low-density lipoprotein receptor-related protein withMafB, a regulator of hindbrain development. [23] Additionally, specific receptors like Tim4 for phosphatidylserine demonstrate the intricate signaling that governs membrane dynamics and cellular processes. [24] These multifaceted regulatory mechanisms ensure precise control over metabolic pathways and cellular function.
Systems-Level Integration and Crosstalk
Section titled “Systems-Level Integration and Crosstalk”Metabolic pathways do not operate in isolation but are extensively integrated through complex crosstalk and network interactions, resulting in emergent physiological properties. Genetic variants can significantly influence these interconnected systems, leading to distinct “metabotypes” that impact individual susceptibility to common multifactorial diseases. [3] For instance, polymorphisms in the FADS1 gene, which codes for delta-5 desaturase, can drastically alter the efficiency of fatty acid desaturation, and this effect can be robustly identified by analyzing ratios of metabolite concentrations, such as eicosatrienoyl-CoA to arachidonyl-CoA. [3] This approach highlights how specific genetic changes propagate through biochemical networks to affect overall metabolic profiles.
Pathway crosstalk is evident in the regulation of lipid metabolism, where nuclear factors like HNF4α and HNF1α not only control cholesterol and bile acid metabolism but also influence the expression of numerous hepatic genes, thus integrating multiple metabolic axes. [19]Such hierarchical regulation ensures that metabolic adjustments are coordinated across different cellular processes. Furthermore, the interaction between genetically determined metabotypes and environmental factors, including nutrition and lifestyle, can significantly modulate an individual’s phenotypic expression and disease risk.[3] These systems-level interactions underscore the complexity of human metabolism and the polygenic nature of many traits.
Pathways in Disease Pathogenesis
Section titled “Pathways in Disease Pathogenesis”Dysregulation within fatty acid and lipid metabolic pathways is fundamentally linked to the pathogenesis of numerous human diseases. Common genetic variants at multiple loci are recognized contributors to polygenic dyslipidemia, a complex condition characterized by abnormal lipid levels that significantly elevates the risk of coronary artery disease.[4] Beyond common variants, specific mutations in genes like ABCG5 lead to monogenic disorders such as sitosterolemia, demonstrating how critical transporters are for preventing pathogenic accumulation of sterols. [14] Similarly, ABCG8variants are associated with gallstone disease susceptibility[25] highlighting its role in cholesterol efflux.
Metabolic pathway dysregulation also extends to neurodevelopmental and psychiatric conditions, with associations between fatty acid desaturase genes, such as theFADS cluster, and attention-deficit/hyperactivity disorder (ADHD). [26] Alterations in fatty acid metabolism and their impact on brain development are further suggested by the moderation of breastfeeding effects on IQ by genetic variation in fatty acid metabolism. [11] Furthermore, conditions like medium-chain acyl-CoA dehydrogenase (MCAD) deficiency arise from genetic variants that reduce enzymatic turnover, leading to specific biochemical phenotypes detected in newborn screening. [13]These examples illustrate how specific mechanistic disruptions in lipid and fatty acid metabolism contribute directly to disease etiology and progression.
Clinical Relevance
Section titled “Clinical Relevance”Genetic Regulation of Fatty Acid Profiles and Metabolic Risk
Section titled “Genetic Regulation of Fatty Acid Profiles and Metabolic Risk”Genetic variants play a significant role in determining the composition of fatty acids within serum phospholipids, which has broad implications for metabolic health. Specifically, loci on chromosome 11, including the FADS1-FADS2gene cluster, encode desaturase enzymes critical for fatty acid metabolism. These desaturases influence the conversion of saturated fatty acids, such as stearic acid (18:0), into unsaturated forms, thereby shaping the overall fatty acid profile[2], [10]. Variations in these genes are strongly associated with the specific fatty acid composition in phospholipids, highlighting a genetic basis for individual differences in fatty acid profiles, including the balance of saturated and unsaturated fatty acids [2], [10].
The influence of these genetic factors on fatty acid composition extends to clinically relevant metabolic traits, including lipid concentrations and the risk of coronary artery disease (CAD). Common genetic variants within theFADSgene cluster have been linked to polyunsaturated fatty acid levels in cohorts of patients with cardiovascular disease[27]. Moreover, newly identified loci, some of which affect fatty acid metabolism, are associated with altered low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or triglyceride levels, and consequently, the risk of CAD[4], [8]. Understanding these genetic determinants of fatty acid profiles, which encompass stearic acid and its metabolic derivatives, offers insights into the etiology and progression of dyslipidemia and associated cardiovascular comorbidities.
Clinical Implications for Risk Stratification and Personalized Medicine
Section titled “Clinical Implications for Risk Stratification and Personalized Medicine”The genetic insights into fatty acid metabolism provide a foundation for improved risk stratification and the development of personalized medicine approaches. Identifying individuals with specific genetic variants that influence fatty acid composition, including the balance involving saturated fatty acids like stearic acid, could help in predicting their susceptibility to metabolic disorders and cardiovascular disease[5]. This knowledge may enable clinicians to identify high-risk individuals earlier, allowing for targeted preventive strategies tailored to their genetic predispositions and fatty acid profiles. Such personalized approaches could go beyond broad dietary recommendations to more specific interventions aimed at optimizing an individual’s fatty acid balance.
Furthermore, genetic associations with various metabolic biomarkers, including specific fatty acid levels, can inform monitoring strategies and potentially guide treatment selection. Genome-wide association studies have identified genes for various biomarkers of cardiovascular disease, and metabolomics studies can further elucidate the genetic architecture of metabolite profiles in human serum[3], [7]. Monitoring genetically influenced changes in fatty acid profiles, which reflect the metabolic status of individuals, could serve as a valuable tool for assessing disease progression, treatment response, and long-term implications for patient care, facilitating more precise management of metabolic and cardiovascular conditions.
References
Section titled “References”[1] Vance, J. E. “Membrane Lipid Biosynthesis.” Encyclopedia of Life Sciences: John Wiley & Sons, Ltd: Chichester, 2001.
[2] Schaeffer L, et al. “Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids.” Hum Mol Genet, vol. 15, no. 11, 2006, pp. 1745-1756. PMID: 16641129.
[3] Gieger C, et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet, 2008.
[4] Kathiresan S, et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 41, no. 1, 2008, pp. 56-65. PMID: 19060906.
[5] O’Donnell, C. J. “Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI’s Framingham Heart Study.”BMC Medical Genetics, vol. 8, S12, 2007.
[6] Yang, Q. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Medical Genetics, vol. 8, S11, 2007.
[7] Benjamin, E. J. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Medical Genetics, vol. 8, S9, 2007.
[8] Willer CJ, et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, vol. 40, no. 2, 2008, pp. 161-169. PMID: 18193043.
[9] Melzer, D. et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genetics, vol. 4, no. 4, 2008, e1000033.
[10] Sabatti, C. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nat Genet, 2008, PMID: 19060910.
[11] Caspi A, et al. “Moderation of breastfeeding effects on the IQ by genetic variation in fatty acid metabolism.” Proc Natl Acad Sci U S A, vol. 104, no. 47, 2007, pp. 18860-18865. PMID: 18003901.
[12] Kuivenhoven JA, et al. “The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.” J Lipid Res, vol. 38, no. 2, 1997, pp. 191-205. PMID: 9162740.
[13] Maier EM, et al. “Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency.” Hum Mutat, vol. 25, no. 5, 2005, pp. 443-452. PMID: 15844299.
[14] Aulchenko YS, et al. “Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.”Nat Genet, vol. 41, no. 1, 2009, pp. 47-55. PMID: 19060911.
[15] Goldstein JL, Brown MS. “Regulation of the mevalonate pathway.” Nature, vol. 343, no. 6257, 1990, pp. 425-430. PMID: 1967820.
[16] Burkhardt R, et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, vol. 28, no. 12, 2008, pp. 2284-2292. PMID: 18802019.
[17] Aalto-Setala K, et al. “Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.”J Clin Invest, vol. 90, no. 5, 1992, pp. 1889-1900. PMID: 1430200.
[18] Yoshida K, et al. “Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase.”J Lipid Res, vol. 43, no. 10, 2002, pp. 1770-1772. PMID: 12401877.
[19] Hayhurst GP, et al. “Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis.” Mol Cell Biol, vol. 21, no. 4, 2001, pp. 1393-1403. PMID: 11158324.
[20] Ma AD, et al. “Pleckstrin associates with plasma membranes and induces the formation of membrane projections: requirements for phosphorylation and the NH2-terminal PH domain.” J Cell Biol, vol. 136, no. 5, 1997, pp. 1071-1079. PMID: 9060471.
[21] Kahle PJ, Haass C. “How does parkin ligate ubiquitin to Parkinson’s disease?”EMBO Rep, vol. 5, no. 7, 2004, pp. 681-685. PMID: 15220803.
[22] Ginsberg J, et al. “Phosphorylation of Heat Shock Protein-90 by TSH in FRTL-5 Thyroid Cells.” Thyroid, vol. 16, no. 8, 2006, pp. 737-742. PMID: 16903875.
[23] Petersen HH, et al. “Low-density lipoprotein receptor-related protein interacts with MafB, a regulator of hindbrain development.”FEBS Lett, vol. 565, no. 1-3, 2004, pp. 23-27. PMID: 15135046.
[24] Miyanishi M, et al. “Identification of Tim4 as a phosphatidylserine receptor.” Nature, vol. 450, no. 7168, 2007, pp. 435-439. PMID: 17960135.
[25] Buch S, et al. “A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease.”Nat Genet, vol. 39, no. 8, 2007, pp. 995-999. PMID: 17632509.
[26] Brookes KJ, et al. “Association of fatty acid desaturase genes with attention-deficit/hyperactivity disorder.” Biol Psychiatry, vol. 60, no. 10, 2006, pp. 1053-1061. PMID: 16682054.
[27] Malerba G, et al. “SNPs of the FADS Gene Cluster are Associated with Polyunsaturated Fatty Acids in a Cohort of Patients with Cardiovascular Disease.”Lipids, vol. 43, no. 3, 2008, pp. 289-299. PMID: 18320340.